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In search for yet uncharacterized proteins involved in lipid metabolism of the chicken, we have isolated a
hitherto unknown protein from the serum lipoprotein fraction with a buoyant density of 1.063 g/ml.
Data obtained by protein microsequencing and molecular cloning of cDNA deﬁned a 537 bp cDNA
encoding a precursor molecule of 178 residues. As determined by SDS-PAGE, the major circulating form
of the protein, which we designate apolipoprotein-VLDL-IV (Apo-IV), has an apparent Mr of approxi-
mately 17 kDa. Northern Blot analysis of different tissues of laying hens revealed Apo-IV expression
mainly in the liver and small intestine, compatible with an involvement of the protein in lipoprotein
metabolism. To further investigate the biology of Apo-IV, we raised an antibody against a GST-Apo-IV
fusion protein, which allowed the detection of the 17-kDa protein in rooster plasma, whereas in
laying hens it was detectable only in the isolated 1.063 g/ml density lipoprotein fraction. Interestingly,
estrogen treatment of roosters caused a reduction of Apo-IV in the liver and in the circulation to levels
similar to those in mature hens. Furthermore, the antibody crossreacted with a 17-kDa protein in quail
plasma, indicating conservation of Apo-IV in avian species. In search for mammalian counterparts of
Apo-IV, alignment of the sequence of the novel chicken protein with those of different mammalian
apolipoproteins revealed stretches with limited similarity to regions of ApoC-IV and possibly with ApoE
from various mammalian species. These data suggest that Apo-IV is a newly identiﬁed avian
apolipoprotein.
 2013 The Authors. Published by Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Several avian species, especially the chicken (Gallus gallus), are
used as model animals to study key molecules and molecular
mechanisms governing lipid metabolism in oviparous species. One
of the most conspicuous aspects of lipid metabolism in birds is the
dramatic difference between mature female and male lipoprotein
proﬁles and apolipoprotein (Apo) expression levels, which are
related to the physiological adaptations required for laying lipid-
rich eggs. Much has been learned about qualitative and quantita-
tive aspects of avian serum lipoproteins and the structure and
function of receptors mediating lipoprotein transport ([1e5]). Thus,
many of the proteins, particularly Apos, involved in avianx: þ43 1 4277 61809.
.at (M. Hermann).
r Masson SAS. Open access under CC lipoprotein metabolism have been identiﬁed and functionally
characterized, but yet unknown components with signiﬁcant roles
in avian lipid metabolic processes presumably do exist. It should be
noted that ApoE, one of the best studied mammalian Apos ([6e8])
is absent in the chicken ([9e11]), and that the existence of a galline
ApoA-II gene remains controversial [12]. We have initiated in-
vestigations of chicken apolipoproteins with known homologues in
mammals, and have described various molecular aspects of ApoB
([13,14]), ApoA-I [15], ApoA-IV ([4,11],), and ApoA-V ([16,17]).
New insights into the spectrum of apolipoprotein components
have been gained from a detailed analysis of serum proteins in
male and female chickens. The classical example is ApoVLDL-II,
discovered by L. Chan and colleagues ([18e21]). To our knowl-
edge, this Apo served as the ﬁrst system for the study of mecha-
nisms of mRNA translation and induction by estrogen ([18,22,23]).
These studies indicated that, as in man, liver and intestine are the
major sources of chicken plasma Apos. ApoVLDL-II is under the
strict control of estrogen ([18,24,25]), which induces the hepatic
synthesis of ApoVLDL-II upon onset of egg-laying. Functional
studies on ApoVLDL-II, a protein not found in mammals, haveBY-NC-ND license.
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that assures the transport of energy-rich lipoproteins to the egg
yolk ([26,27]). In the current study, we have identiﬁed and char-
acterized a second chicken apolipoprotein that appears to be ab-
sent from mammals. The 17-kDa apoprotein, which we designate
ApoVLDL-IV (in short, Apo-IV), is primarily synthesized in liver
and intestine, and its plasma levels are higher in mature roosters
than in laying hens. A mammalian counterpart of Apo-IV could not
be identiﬁed, albeit protein sequence alignment of chicken Apo-IV
with different mammalian Apos suggested regions with similarity
to rabbit ApoC-IV.
2. Material and methods
2.1. Animals
Mature Derco-Brown (TETRA-SL) hens and roosters (30e40
weeks old) were purchased from Diglas Co. (Feuersbrunn, Austria).
Fertilized eggs were incubated under standard conditions for
temperature (37.5 C) and humidity (60e70%). Japanese quail of
both sexes and 16 weeks of age were purchased from the Institute
of Animal Biochemistry and Genetics, Slovak Academy of Sciences
(Ivanka pri Dunaji, Slovak Republic). The birds were fed a com-
mercial layer mash diet with free access to water and feed at 20 C
with a daily light period of 16 h. Where indicated, roosters were
treated by intramuscular injection with 10 mg/kg body weight of
17a-ethinylestradiol (Sigma) (stock solution, 40 mg/ml 1,2-
propanediol) either once, or every 24 h for up to 3 times, and
euthanized by decapitation for tissue and organ retrieval. Adult
female New Zealand White rabbits (Sommer, Wollmersdorf,
Austria) and Balb/c mice (Institute of Biomedical Research, Medical
University of Vienna, Austria) were obtained from the indicated
sources. All animal procedures were approved by the “Animal Care
and Use Committee” of the Medical University of Vienna.
2.2. Protein expression and antibodies
A 351-bp cDNA fragment coding for the central portion of
chicken apo-IV was cloned into the pGEX-5X-1 expression vector
(Amersham Pharmacia Biotech) for expression of a GST-Apo-IV
fusion protein. The primers were as follows: forward, 50-
CAGAATTCGGGGCGTGTGGGGCTGAG-30 (EcoRI site in bold face);
and reverse 50-GCGGCCGCTTACTGCCCCCTCCCTCTCCA-30 (NotI site
in bold face, and stop codon underlined). The recombinant GST-
Apo-IV was expressed in Top10 F0 cells (Invitrogen), and,
following induction with 3 mM IPTG, was puriﬁed under native
conditions using Glutathione Sepharose 4B (Amersham Pharma-
cia Biotech). Adult female New Zealand White rabbits and female
Balb/c mice were used for raising polyclonal antibodies against the
GST-Apo-IV fusion protein. Rabbit antiserum against recombinant
Apo-IV was obtained by intradermal injections of 250 mg each of
antigen as described previously [28]. Mouse polyclonal antiserum
against recombinant apo-IV was obtained by 4 intraperitoneal in-
jections of 50 mg each of antigen on days 0, 28, 56, and 84. Antisera
were tested by Western blotting using preimmune serum as con-
trol. Rabbit Anti-ApoVLDL-II antibody was obtained as previously
described [29].
2.3. Lipoprotein isolation
Individual blood samples were collected from the wing veins of
laying hens, mature roosters (23G 0.60  30 mm needle, 10 ml
syringe), and quail (26G 0.45  25 mm needle, 2 ml syringe) into
tubes containing EDTA (ﬁnal concentration, 10 mM), and plasma
was separated by centrifugation at 3000  g for 15 min at 4 C.Separation of lipoprotein classes by step gradient ultracentrifuga-
tion was performed according to Kelley [30]; 1 ml-fractions were
collected from the bottom of the tube, and the density of each
fractionwas determined. After delipidation, the Apo-IV distribution
was analyzed by Western blotting. For the isolation of lipoproteins
with densities of1.210 or1.063 g/ml, plasmawas adjusted to the
respective density by adding solid KBr, and the lipoproteins were
ﬂoated by ultracentrifugation in a TLA 100.3 rotor at 90.000 rpm for
3 h using a Beckman Optima TLX ultracentrifuge (Beckman In-
struments). The VLDL fraction from yolk of freshly layed eggs
(yVLDL) was prepared as described [14]. The lipoprotein samples
were recovered with a syringe and delipidated in diethylether/
ethanol (3:1, v/v) as previously described [29].
2.4. Microsequencing
The lipoprotein fraction of d  1.063 of rooster plasma was
isolated by ultracentrifugal ﬂoatation, delipidated, the residue
subjected to SDS-polyacrylamide gel electrophoresis, and blotted
onto a polyvinylidene diﬂuoride membrane (Immobilon P,
0.45mm,Millipore Corp., Bedford, MA). Microsequencing of the 17-
kDa protein was performed as previously described [31,32].
2.5. Preparation of Triton X-100 protein extracts
Chickens were euthanized as described above and tissues were
placed in ice-cold homogenization buffer (4 ml/g wet weight)
containing 20 mM HEPES, 300 mM sucrose, 150 mM NaCl, pH7.4,
and complete EDTA-free protease inhibitor tablets (Roche), and
homogenized with an UltraeTurrax T25 homogenizer. The ho-
mogenates were centrifuged for 10 min at 620  g and 4 C, and 1/
20 volume of 20% Triton X-100 was added to the resulting super-
natant. After incubation for 30 min at 4 C, the mixture was
ultracentrifuged using a TLA 100.3 rotor at 50,000 rpm for 1 h using
a Beckman Optima TLX ultracentrifuge (Beckman Instruments).
Protein concentrations of the extracts were determined by the
method of Bradford using the Coomassie Plus assay from Pierce.
2.6. SDS-PAGE and Western Blotting
Plasma, delipidated lipoproteins, and protein extracts were
analyzed by one-dimensional 12% SDS-PAGE under reducing (in the
presence of 50 mM DTT) or non-reducing conditions, and either
stained with Coomassie Blue or electrophoretically transferred to
nitrocellulose membranes (Hybond-C Extra, Amersham Pharmacia
Biotech) for Western Blotting. Nonspeciﬁc binding sites were
blocked with TBS (25 mM Tris, 140 mM NaCl, 25 mM KCl, pH7.4)
containing 5% nonfat dry milk and 0.1% Tween-20 for 1 h at room
temperature. Apo-IV was detected with rabbit anti-GST-Apo-IV
antiserum or with mouse anti-GST-Apo-IV antiserum at the indi-
cated concentrations, followed by incubation with HRP-conjugated
goat anti-rabbit IgG or anti-mouse IgG from Sigma (1:40,000 or
1:1500 dilution), respectively, and developed with the Enhanced
Chemiluminescence protocol (Pierce). The sizes of the proteins
were estimated using a set of molecular mass standards (10e
250 kDa, Bio-Rad).
2.7. cDNA preparation, PCR analysis, and cDNA cloning
Total RNA was isolated using the NucleoSpin RNAII kit (March-
erey-Nagel), and cDNA was prepared using Superscript RNase H-
(Invitrogen). PCR ampliﬁcation was carried out using High Fidelity
PCR EnzymeMix from Fermentas. The sequence ofGallus gallus cDNA
clone ChEST494i21 (NCBI CR389711.1) was used for primer design.
Primers were: forward, 50-TATAGGGTCGATGGGGGACT-30; and
Fig. 1. Analysis of proteins in the lipoprotein fraction of chicken serum. The apolipo-
proteins present in the serum fraction containing lipoproteins with densities of
d  1.21 g/ml of laying hen (LH) and rooster serum was analyzed by SDS-PAGE. One ml
of the indicated fraction was separated on a 4.5e18% gradient SDS-polyacrylamide gel
under non-reducing conditions, followed by Coomassie Blue staining. The positions of
the known apolipoproteins, apoB-100, apoA-I, and mono- and dimeric apo-VLDL-II, as
well as of the hitherto unknown protein of 17-kDa size (apo-IV) are indicated.
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as follows: 1min 94 C,1min 62 C,1min 72 C, 3 cycles; 1min 94 C,
1min58 C,1min72 C, 3 cycles; 1min94 C,1min54 C,1min72 C,
34 cycles. PCR products were subjected to electrophoresis on a 1%
agarose gel and puriﬁed using QIAquick gel extraction kit (Qiagen).
Fragments were cloned into the pCR2.1-TOPO vector using the TOPO
TA Cloning kit (Invitrogen) and transformed into Top10 cells (Invi-
trogen). DNA sequencing was carried out by VBC-BIOTECH (Vienna,
Austria).
2.8. Northern Blot analysis
Total RNAs (30 mg each), isolated from different laying hen tis-
sues using TRI Reagent (Molecular Research Center, Inc.), were
denatured using glyoxal and separated on a 1.2% agarose gel in
10mM sodium phosphate buffer, pH 6.8. After transfer to Hybond N
membrane (Amersham Pharmacia Biotech), RNA was immobilized
by UV cross-linking, and the membrane was hybridized overnight
at 65 C with a 32P labeled 492-bp PCR-ampliﬁed Apo-IV cDNA
fragment (Megaprime DNA labeling kit, Amersham Pharmacia
Biotech) in 1% BSA, 7% SDS, 0.5 M sodium phosphate buffer pH 6.8,
and 1 mM EDTA. The primers used to amplify the probe were as
follows: forward, 50-TCTATAGGGTCGATGGGGGACTTTG-30; and
reverse, 50-CTGCCCCCTCCCTCTCCAGCGCTCC-30. Washing was per-
formed at 65 C in 5% SDS, 40 mM sodium phosphate buffer pH 6.8,
1 mM EDTA, and in 0.5% BSA, 1% SDS, 1 mM EDTA, and 40 mM
sodium phosphate buffer pH 6.8. Autoradiography was performed
at 80 C. The relative amounts of RNA loaded were estimated
using methylene blue staining of ribosomal RNA.
2.9. Cell culture
Chicken liver cells were isolated from newly hatched chicks of
mixed sex as described previously [33] with minor modiﬁcations.
Tissue slices were digested with a solution of 1 mg/ml type II
collagenase (Sigma) to generate a single-cell suspension. The liver
cells were grown in monolayer culture in DME medium supple-
mented with 20 mM Glucose, 5% chicken serum, 1% penicillin-
streptomycin, 2 mM L-glutamin, at 37 C in an atmosphere of 7.5%
CO2/92.5% air. Medium was changed every 24 h. Where indicated,
cultured cells were incubated with moxestrol, a synthetic analog of
17-b-estradiol, at a ﬁnal concentration of 50 nM for 24 h [13].
3. Results
3.1. Identiﬁcation of a new chicken apolipoprotein
Separation by SDS-polyacrylamide gel electrophoresis of the
proteins present in the total lipoprotein fraction of chicken plasma
resulted in the identiﬁcation of a protein, which to our knowledge
has not been described previously. As shown in Fig. 1, the major
proteins in the d  1.21 g/ml fraction of laying hen plasma were
ApoB, ApoA-I, and the strictly estrogen-dependent Apo-VLDL-II
displaying mono- and dimeric forms ([29,26,27]). The lipoprotein-
associated proteins in rooster plasma were predominantly ApoB
and ApoA-I, with an additional protein that was apparently absent
from the fraction isolated from laying hen plasma. The relative
mobility of this protein on SDS-polyacrylamide gels indicated an
apparentMr of 17 kDa (Fig. 1). Microsequencing of the 17-kDa band
resulted in four peptide sequences: H2N-Glu-Thr-Pro-Thr-Pro-Glu-
Thr-Pro-Leu-Ala-Pro-Leu-Thr, Arg-Leu-Trp-Gly-Ser-Asp-Val-Gly-
Gln-Thr-Val-Gln-Ser-Leu-Leu-Thr-Val-Leu-Arg, Arg-Val-Ala-Glu-
Tyr-Gly-Ala-Glu-Val-Glu-Gln-Ser-Val-Ala-Ser-Leu-Ser, and Arg-
Trp-Gly-Gln-Tyr-Arg. The sequences of all 4 peptides were repre-
sented in the cDNA clone Gallus gallus ChEST494i21 (NCBI;GenBank CR389711.1). In addition, 3 in-frame methionine residues
upstream of the amino-terminal Glu were identiﬁed in the trans-
lated sequence. The closest upstreamMet is located at position18,
and is separated from the Glu by a peptide with predominantly
hydrophobic residues, MLLVTVVAAAALLGACGA, possibly repre-
senting the signal sequence for secretion, while the other two Met
residues were not followed by such sequences. The ChEST494i21
sequence was used to produce a 538 bp cDNA fragment by RT-PCR,
using RNA from laying hen small intestine with the primer pair
(indicated in Fig. 2) 50-TATAGGGTCGATGGGGGACT-30 and 50-
CCCCCAAAACAACCCCTC-30. Northern blot experiments demon-
strated that chicken liver and intestine express the highest levels of
the speciﬁc transcript with a size of approximately 830 nt. Weak
signals were also obtained in kidney, abdominal fat, and adrenal
gland after prolonged exposure (Fig. 3). This result is in agreement
with the tissue expression of clone ChEST494i21 reported in NCBI’s
EST Proﬁle, Gga.18119.3.2. Generation of antibodies and immunological analysis of Apo-IV
in avian plasma
To obtain an immunological tool for the analysis of Apo-IV, the
protein was expressed as a GST fusion protein in Top10 F0 cells,
puriﬁed, and used to generate antisera in rabbits as well as mice. As
shown in Fig. 4A, the rabbit antiserum recognized the recombinant
GST-Apo-IV fusion protein at 40 kDa and Apo-IV in rooster plasma
at 17 kDa; pre-immune serum showed no reactivity. Next, we
Fig. 2. Nucleotide and amino acid sequences of Apo-IV. The novel protein (see Fig. 1) was isolated from the chicken serum fraction containing lipoproteins with densities of
1.063 g/ml. By microsequencing and molecular cloning, we obtained a 537 bp cDNA encoding a 121 residue mature protein. Numbering starts after the predicted signal cleavage
site, which is indicated by the arrow. Primers are highlighted in gray, and peptides obtained by microsequencing are underlined.
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density range from 1.006 to 1.21 g/ml, collected fractions, and
tested aliquots by Western blotting for the presence of the protein.
Analysis of the plasma fractions with the rabbit anti-GST-Apo-IV
antiserum (Fig. 4B) revealed that Apo-IV in plasma is present in 3
fractions at and near the top of the tube, likely representing LDL and
VLDL, at densities at and smaller than 1.063 g/ml.
Based on this result, we prepared the d  1.063 lipoprotein
fractions of the plasma of laying hens and roosters to enrich for
Apo-IV. While the protein was indeed clearly present in these li-
poprotein fractions of both, hen and rooster (Fig. 5, lanes 1 and 2),
the rabbit anti-Apo-IV antiserum detected the 17-kDa protein only
in unfractionated plasma of roosters, but not of laying hens (Fig. 5,
lanes 3 and 4), in agreement with the results of Fig. 1. In addition, in
quail rooster plasma we identiﬁed a cross-reactive band, likely
representing the quail analog of the galline Apo-IV protein (Fig. 5,
lane 5). When the incubation medium contained GST-Apo-IV, no
signal was observed (Fig. 5, lanes 6e10), demonstrating theFig. 3. Northern blot analysis of Apo-IV mRNA tissue distribution. Total RNA (30 mg) isolat
bridized with a 32P labeled 492-bp PCR fragment. The position of migration of marker RN
staining (lower panel). After 2 d exposure, Apo-IV mRNAwas detected in the liver and small
adrenals, and abdominal fat (lanes to the right). Stroma, ovarian follicle tissue; Granulosa, gspeciﬁcity of the immunoreaction; furthermore, preimmune serum
showed no reactivity (Fig. 5, lanes 11e15).
3.3. Effect of estrogen
Next, we tested whether hepatic Apo-IV expression is estrogen-
sensitive. To directly investigate the effects of estrogen in vivo, we
treatedmature roosters with or without the hormone and analyzed
liver extracts by Western blotting. Estrogen treatment of male
chickens induces dramatic changes in gene expression levels and
hepatic lipid metabolism ([18,34e37]). As shown in Fig. 6A (lanes 1
and 2), hepatic Apo-IV levels in laying hens were much lower than
in untreated roosters, as expected; a single dose of estrogen
administered to roosters dramatically reduced hepatic Apo-IV
within 24 h (compare lanes 2 and 3), after which the level rose
and, at 72 h after estrogen administration, reached that observed
before treatment (lane 5). In contrast to the single-dose estrogen
treatment, multiple estrogen administrations (3 times at 24 hed from the indicated laying hen tissues was separated on a 1.2% agarose gel and hy-
As (bases) is indicated. The amount of blotted RNA was visualized by methylene blue
intestine (2 lanes on the left). After 5 d exposure, weak signals were obtained in kidney,
ranulosa cells isolated from a mature ovarian follicle.
Fig. 4. Immunological analysis of Apo-IV in chicken plasma. (A): Reactivity of GST-Apo-IV antiserum. Lane 1, GST-Apo-IV fusion protein in Top10 cells; lanes 2 and 3, 1 ml rooster
plasma. Lanes 1 and 2 were incubated with rabbit anti-GST-Apo-IV antiserum (dilution, 1:250), and lane 3 with rabbit preimmune serum (1:250). For all 3 lanes, peroxidase-
conjugated goat anti-rabbit IgG was used as detection antibody. (B): Rooster plasma was subjected to density gradient ultracentrifugation as described in Materials and
methods. Fractions of 1 ml volume were collected from the top of the tube, and 10 ml of each fraction were analyzed by 15% SDS-PAGE under non-reducing conditions. One ml
rooster plasma served as control (left lane); fractions 1e12 had densities from 1.006 to 1.210 g/ml; Bottom, proteins sedimented in a soft pellet at the bottom of the tube after
ultracentrifugation. In all samples, Apo-IV was analyzed by Western blotting with rabbit anti-GST-Apo-IV antiserum (dilution 1:250) and peroxidase-conjugated goat anti-rabbit
IgG.
Fig. 5. Detection of Apo-IV in chicken and quail plasma. Plasma lipoproteins with densities of 1.063 g/ml were delipidated, and 50 mg apolipoproteins from laying hen (lanes 1, 6,
11) or rooster (lanes 2, 7, 12), or 1 ml of whole plasma from laying hen (lanes 3, 8, 13), rooster (lanes 4, 9, 14), and quail rooster (lanes 5, 10, 15) were separated under reducing
conditions on 12% SDS-polyacrylamide gels. After transfer to membranes, the blots in lanes 1e10 were incubated with rabbit anti-GST-Apo-IV antiserum (dilution 1:250) in the
absence (lanes 1e5) or presence (lanes 6e10) of 10 mg/ml GST-Apo-IV, followed by peroxidase-conjugated goat anti-rabbit IgG. In lanes 11e15, preimmune rabbit serum was used
instead of the anti-GST-Apo-IV rabbit antiserum.
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Fig. 6. Effect of estrogen administration on Apo-IV levels in the liver of roosters (A) and cultured hepatocytes (B). (A): Liver extracts (70 mg protein/lane) from laying hen (LH, lane 1),
rooster (Ro, lane 2), and roosters treated with estrogen (Ro þ E2; lanes 3e8) were separated by 12% SDS-PAGE under non-reducing conditions. The roosters had been treated as
follows: a single dose (10 mg/kg body weight) at 0 h, euthanized at 24 h (lane 3); a single dose at 0 h, euthanized at 48 h (lane 4); a single dose at 0 h, euthanized at 72 h (lane 5); 1
dose at 0 h, euthanized at 24 h (lane 6); 1 dose each at 0 and 24 h, euthanized at 48 h (lane 7); and 1 dose each at 0, 24, and 48 h, euthanized at 72 h (lane 8). Tissue extracts were
prepared as described in Materials and methods. (B): Cultured primary chicken hepatocytes were harvested before (lane 1) or after incubation for 24 h with 50 nM moxestrol (lane
2). Cell lysates (40 mg protein/lane) were separated by 12% SDS-PAGE in the presence of 50 mM DTT. In (A) and (B), Apo-IV was visualized by Western blot analysis using our mouse
anti-GST-Apo-IV antiserum (dilution 1:1500), followed by peroxidase-conjugated rabbit anti-mouse IgG.
B. Nikolay et al. / Biochimie 95 (2013) 2445e24532450intervals) led to a persistently decreased Apo-IV protein level over
the entire treatment period (Fig. 6A, lanes 6e8). Furthermore, to
gain insight into the effect of estrogen at the cellular level, we
isolated primary liver cells from 1- to 3-day old chicks of mixed sex
and treated themwith the synthetic estrogen, moxestrol. As shown
in Fig. 6B, cellular Apo-IV protein clearly decreased after incubation
with estrogen for 24 h. These data, together with our observations
in roosters in comparison to hens, establish that Apo-IV expression
is directly suppressed by estrogen both in vitro and in vivo.
Finally, we tested whether Apo-IV-containing VLDL particles
accumulate in the yolk of oocytes. One important property of yolk-
targeted VLDL particles is that they harbor the unique protein
ApoVLDL-II [26]. As shown in Fig. 7 for control purposes, laying hen
plasma and VLDL isolated from yolk indeed contains ApoVLDL-II,
whereas Apo-IV is present only in plasma. Even though in this
experiment we used our mouse anti-GST-Apo-IV antiserum, which
has greater sensitivity towards the antigen than our rabbit anti-
GST-Apo-IV antiserum (see Fig. 5, lanes 3 and 4, where the rabbit
antiserum did not detect Apo-IV in hen plasma), Apo-IV in yolk
VLDL was not detected by Western blotting. Thus, it appears that
Apo-IV-containing VLDL particles are, at least to a signiﬁcant
extent, excluded from uptake into yolk.Fig. 7. Yolk VLDL does not harbor detectable amounts of Apo-IV. One ml of plasma from
laying hen (LH) or rooster, or 50 mg delipidated VLDL isolated from egg yolk (yVLDL)
were separated by 12% (A) or 15% (B) SDS-PAGE in the presence of 50 mM DTT. (A)
Western blotting analysis of Apo-IV using mouse anti-GST-Apo-IV antiserum (dilution
1:1500), followed by peroxidase-conjugated rabbit anti-mouse IgG. (B) ApoVLDL-II was
visualized by Western blot analysis using rabbit anti-apoVLDL-II antiserum (dilution
1:1500) and peroxidase-conjugated goat anti-rabbit IgG.4. Discussion
This study describes a hitherto unknown chicken apolipoprotein
present in the plasma fraction containing lipoproteins with den-
sities of 1.063 g/ml. The levels of the novel 17-kDa protein, which
we designate Gallus gallus apolipoprotein-VLDL-IV (Apo-IV), differ
between hens and roosters, and are negatively regulated by es-
trogen in vitro and in vivo. In the course of our extensive literature
search for other apolipoproteins that may show negative estrogen
responsiveness, we became aware of a study [38], which describes
a protein in VLDL of untreated, but not estrogen-treated roosters
with a reported apparent size (on SDS-polyacrylamide gels) of
B. Nikolay et al. / Biochimie 95 (2013) 2445e2453 245119 kDa (Fig. 2, lanes 4 and 5 in Ref. [38]). In addition, Miller and Lane
([24]) compared the apolipoprotein composition of VLDL secreted
by cultured chick hepatocytes under control and estradiol-induced
conditions. One particular difference between the two conditions
was observed in the levels of a protein whose molecular mass was
estimated at 17 kDa. The authors found that the relative secretion
rate of this apoprotein decreased from 10 to 4% upon exposure of
the hepatocytes to estradiol ([24]). However, we are not aware of
any subsequent reports about properties of this/these candidate
chicken apolipoprotein(s).
The molecular characterization of the protein identiﬁed in the
current work revealed several interesting properties. Extensive
analyses of DNA- and protein sequence data bases failed to identify
a mammalian protein with signiﬁcant similarity to Apo-IV. There
are two stretches with resemblance to ApoC-IV proteins in mam-
mals, particularly in rabbit [39], one of which is a proline-rich motif
located at the aminoterminus (identiﬁed by protein micro-
sequencing, see Fig. 2) of both proteins. The proline-rich sequences
are ETPTPETPLAPL and EPEGTPTPLPAP in Apo-IV and rabbit Apo-
C-IV, respectively. The other region of similarity is speciﬁed by
LWGSDVGQTVQSLLTVLR (Apo-IV) and LVPSSVKELVGPLLTRTR
(rabbit Apo-C-IV). However, these two stretches are separated by
different numbers of residues in the two proteins (16 in the chicken
protein, 6 in rabbit Apo-C-IV). Furthermore, the remaining se-
quences cannot be aligned in any meaningful way. In man, the gene
encoding ApoC-IV is part of a cluster encoding ApoE, ApoC-I, ApoC-
IV, and ApoC-II, located on chromosome 19 ([40e42]). Likewise, the
genes for human Apo-AI, ApoA-IV, ApoA-V, and ApoC-III form a
cluster on chromosome 11 (region q23) [43].
While a gene cluster homologous to that at human 11q23 is
located on chicken chromosome 24 (see, e.g. [16]), the question of
whether there is an ApoE/C-I/C-IV/C-II cluster in chicken or any
other avian species remains unanswered. To address the
complexity of this question, we need to consider that while lipid
metabolic pathways in birds andmammals share several important
properties, they also show signiﬁcantly different features, particu-
larly in lipoproteins of intestinal and peripheral origin ([4,44],).
Accordingly, certain mammalian apolipoproteins are apparently
absent from or divergent in aves, and vice versa. First, speciﬁc dif-
ferences to mammals include features of avian apolipoprotein B
(apoB), which serves an essential role in the assembly and secretion
of triglyceride-rich lipoproteins and in lipid transport. In mammals,
plasma apoB exists in two forms, i.e. apoB-48, found in intestinally
synthesized chylomicrons, and apoB-100 ([45,46]), derived from
hepatic synthesis. In the chicken only apoB-100 [47] is produced in
both the liver and intestine. ApoB-100, but not apoB-48, contains
the binding domain recognized by the LDL receptor, VLDL receptor,
and LDL receptor-related protein 1 (LRP1) in mammals and chicken
[2]. Second, in mammals, apolipoprotein E (ApoE) is a constituent of
chylomicrons, chylomicron remnants, VLDL, and speciﬁc HDL sub-
classes (HDL1, HDLc) with high binding afﬁnity for the LDL receptor
and other apoB/E receptors ([48e50]). An ApoE or ApoE-like pro-
tein in chicken has not been demonstrated to date ([4,9,10]). Third,
in humans, apolipoprotein A-I (ApoA-I), a major protein constituent
of plasma high-density lipoproteins (HDLs), is synthesized only in
the liver and intestine [51]. On the other hand, chicken ApoA-I is the
major apolipoprotein component of HDL, but it is also found on
VLDL, IDL, and LDL, and unique yolk-sac derived lipoprotein parti-
cles ([9,52,53]). In adult birds, ApoA-I is synthesized in the liver and
intestine [54], but in contrast to mammals, chicken apoA-I mRNA
and protein synthesis were also detected in several peripheral tis-
sues such as skin, kidney, ovarian granulosa, and yolk sac endo-
dermal epithelial cells ([10,53,55e57]). Fourth, mammalian HDL
contains a second major component, apolipoprotein A-II (apoA-II).
In chicken, to date an ApoA-II homologue has not beencharacterized beyond doubt ([12,58]). For instance, the DFCI Gallus
gallus Gene Index (GgGI) lists TC424643 as the most relevant EST,
which is, however, only 38% identical with human ApoA-II in two
stretches comprising 71 residues, whereas bona-ﬁde galline apo-
lipoproteins in general show at least 73% identity with mammalian
homologues. Fifth, human ApoA-IV is synthesized by liver and in-
testine, and as a prominent component of newly secreted chylo-
microns is delivered into the lymph and reaches the plasma via the
thoracic duct. Chicken ApoA-IV is synthesized primarily in the in-
testine ([4,11]); however, in contrast to mammals, in birds intesti-
nally synthesized lipoproteins are not delivered to the lymphatic
system. Instead, they are secreted directly into the portal vein as so-
called portomicrons [44], which are rapidly taken up by the liver
mediated by a yet unidentiﬁed receptor. Sixth, human ApoA-V,
expressed in the liver, plays a key role in the regulation of triglyc-
eride metabolism ([43,59]). In chicken, ApoA-V is expressed in liver
and small intestine and also in brain, kidney, and ovarian follicles,
and binds to the major chicken LDL receptor family member, LR8
[16]. Seventh, the ApoCs comprise four low molecular weight apo-
lipoproteins, designated ApoC-I, -C-II, -C-III, and -C-IV. In mam-
mals, during postprandial lipemia, ApoCs relocate, at least in part,
from HDL to nascent chylomicrons and are returned to HDL upon
lipoprotein lipase (LPL)-mediated metabolism of chylomicrons
[60]. ApoC-I, the smallest apo in mammals, has several clearly
deﬁned functions ([61,62]), but a chicken ApoC-I homolog has not
been identiﬁed to date. ApoC-II plays a crucial role as cofactor of LPL
in mammalian as well as galline lipoprotein metabolism ([63e65]).
In contrast, whereas human apoC-III is a recognized regulator of
lipoprotein metabolism via inhibition of LPL as well as binding of
lipoproteins to cell surface heparan sulfate proteoglycans and re-
ceptors ([66,67]), the chicken homologue has not been character-
ized to date. The most recently identiﬁed member of the apoC-
family is mammalian apoC-IV ([39,68]), which is predominantly
found in the VLDL plasma fraction, but at concentrations much
lower than that of other apoCs. Again, in the chicken, apoC-IV has
not been identiﬁed to date. Finally, thus far only one apolipoprotein
that is absent frommammals has been identiﬁed and characterized
in birds, i.e., ApoVLDL-II, a unique inhibitor of LPL in laying hens
[26]. As mentioned in Introduction, expression of ApoVLDL-II is
strictly estrogen-dependent ([18,24,25]), assuring the induction of
hepatic synthesis of apoVLDL-II exactly upon onset of egg-laying.
Thus, the above described metabolic features and the available
data at the molecular level indicate strongly that chickens lack a
gene cluster that could be considered homologous to the
mammalian ApoE/C-I/C-IV/C-II region. Consequently, the similarity
between 2 short regions in chicken Apo-IV and rabbit ApoC-IV,
albeit intriguing, may merely indicate a distant evolutionary rela-
tionship between Apo-IV and mammalian ApoCs, as expected for
small lipophilic proteins with modulatory roles in lipoprotein
metabolism. In contrast to chicken ApoB and ApoVLDL-II, two key
apolipoproteins in the hormone-induced process of egg laying,
Apo-IV expression responds negatively to estrogen, a property that
likely explains the difference in serum and hepatic levels of the
protein in mature roosters and hens (Figs. 5 and 6). The only other
known chicken apolipoprotein that shows reduced expression
under the inﬂuence of estrogen is ApoA-I ([15,69,70]). ApoA-I does
not appear to play a direct role in the egg-laying process, but may
have an indirect effect on the production of oocyte-directed VLDL
particles, which require large amounts of ApoVLDL-II and ApoB for
rapid assembly. In this context, the metabolic characteristics of
Apo-IV and ApoA-I in the chicken show a further analogy, i.e., their
lack of detectable uptake into oocytic yolk (Fig. 7) and [71]. While
the majority of VLDL particles are taken up into oocytes via an
oocyte-speciﬁc chicken homologue of the human VLDL receptor,
termed LR8 ([3,72],), Walzem et al. [37] have suggested that there is
B. Nikolay et al. / Biochimie 95 (2013) 2445e24532452a population of VLDL particles different from this major fraction.
The results of Fig. 7 are in agreement with this possibility, as they
indicate that VLDL particles containing Apo-IV are excluded from
oocytic uptake, possibly by interfering with binding to LR8. The
Apo-IV-containing subfraction, however, may well satisfy nutrient
requirements of somatic cells, which do not rely on LR8 for lipo-
protein uptake ([1]). Such ametabolic role for the ApoIV-containing
VLDL particles would be more important in roosters than in hens,
where massive estrogen-induced VLDL production provides large
amounts of components to oocytes as well as somatic cells. In fact,
estrogen-induced ApoVLDL-II is an important regulator of differ-
ential lipoprotein ﬂow between somatic and germ cells in laying
hens; by analogy, this may be the function of the estrogen-sensitive
Apo-IV in roosters. Further investigations along these lines are now
underway.Acknowledgments
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